Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Fr | Omega Therapeutics stock hits 52-week low at $0.89 | 2 | Investing.com | ||
OMEGA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
Fr | Omega Therapeutics-Aktie erreicht 52-Wochen-Tief bei 0,89 US-Dollar | - | Investing.com Deutsch | ||
Fr | Omega Therapeutics reports Q3 results | 1 | Seeking Alpha | ||
15.10. | Omega Therapeutics to Present Multiple Posters Highlighting Versatile Platform Capabilities at Upcoming Scientific Meetings | 8 | GlobeNewswire (USA) | ||
07.10. | Aktie von Omega Therapeutics erreicht 52-Wochen-Tief bei 1,07 US-Dollar | 5 | Investing.com Deutsch | ||
07.10. | Omega Therapeutics stock hits 52-week low at $1.07 | 2 | Investing.com | ||
04.10. | Omega Therapeutics beruft neues Vorstandsmitglied | 2 | Investing.com Deutsch | ||
04.10. | Omega Therapeutics Appoints New Director | 2 | Investing.com | ||
04.10. | Omega Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
30.09. | Omega Therapeutics-Aktie erreicht 52-Wochen-Tief bei 1,2 US-Dollar | 2 | Investing.com Deutsch | ||
30.09. | Omega Therapeutics stock hits 52-week low at $1.2 | 2 | Investing.com | ||
17.09. | Omega Therapeutics reports tumor inhibition in liver cancer models | 3 | Investing.com | ||
17.09. | Omega Therapeutics Announces Publication of Epigenomic Controller OTX-2002 Preclinical Data in Nature Communications | 110 | GlobeNewswire (Europe) | Treatment with OTX-2002 led to controlled downregulation of MYC gene expression and resulted in significant inhibition of tumor growth as a monotherapy and in combination with standard of care agents... ► Artikel lesen | |
06.09. | Omega Therapeutics stock hits 52-week low at $1.29 amid downturn | 1 | Investing.com | ||
30.08. | Omega Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
15.08. | A Glimpse Into The Expert Outlook On Omega Therapeutics Through 4 Analysts | 1 | Benzinga.com | ||
14.08. | Omega Therapeutics appoints new SVP of Research | 1 | Investing.com | ||
14.08. | Omega Therapeutics Announces Jennifer Nelson, Ph.D., as Senior Vice President of Research | 2 | GlobeNewswire (USA) | ||
06.08. | Omega Therapeutics GAAP EPS of -$0.30, revenue of $2.13M | 1 | Seeking Alpha | ||
06.08. | Omega Therapeutics Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress | 106 | GlobeNewswire (Europe) | Advanced MYCHELANGELO I trial; Company expects to select recommended dose for expansion and initiate monotherapy and combination expansion cohorts in fourth quarter of 2024Reinforced diverse capabilities... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
EVOTEC | 9,895 | -0,10 % | EQS-Adhoc: Evotec SE: Kommentar zu Medienbericht | EQS-Ad-hoc: Evotec SE / Schlagwort(e): Sonstiges
Kommentar zu Medienbericht
14.11.2024 / 22:51 CET/CEST
Veröffentlichung einer Insiderinformation nach Artikel 17 der Verordnung (EU) Nr.... ► Artikel lesen | |
BB BIOTECH | 38,500 | -0,39 % | PTA-News: Small- & MicroCap Investment: BB Biotech, Bright Minds, NurExone: Biotech-Konzerne sichern sich erfolgreich Privatplatzierungen | DJ PTA-News: Small- & MicroCap Investment: BB Biotech, Bright Minds, NurExone: Biotech-Konzerne sichern sich erfolgreich Privatplatzierungen
Unternehmensmitteilung für den Kapitalmarkt
Frankfurt... ► Artikel lesen | |
CUREVAC | 2,312 | -2,69 % | CureVac mit BRANDNEUER Prognose: Steht die Aktie jetzt vor einem Kursdebakel - Sofortiges HANDELN erforderlich! | ||
EPIGENOMICS | 0,900 | -21,74 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
INTELLIA THERAPEUTICS | 13,300 | +6,87 % | Gen-Schere Hoffnungsträger Intellia Therapeutics: Aktie mit Kurssprung - die Hintergründe | Das Gros der Biotech- und Pharmawerte hat in den vergangenen Tagen nach der Ankündigung Donald Trumps, Robert F. Kennedy Jr. als Gesundheitsminister für die künftige Regierung nominieren zu wollen,... ► Artikel lesen | |
DEFENCE THERAPEUTICS | 0,384 | +3,78 % | Defence Therapeutics Inc.: Defence Therapeutics Announces Securities for Debenture Financing | Vancouver, British Columbia--(Newsfile Corp. - November 14, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen | |
AFFIMED | 2,610 | -0,38 % | Affimed N.V.: Affimed Reports Third Quarter 2024 Financial Results & Business Update | AFM24 combination with atezolizumab: The non-small cell lung cancer (NSCLC) EGFR wild-type (EGFRwt) cohort completed enrollment: Objective response rate (ORR) and safety data to be presented on a... ► Artikel lesen | |
GINKGO BIOWORKS | 6,000 | -0,83 % | Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Sees Significant Drop in Short Interest | ||
RECURSION PHARMACEUTICALS | 5,860 | -2,98 % | Recursion Pharmaceuticals, Inc.: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will... ► Artikel lesen | |
BEAM THERAPEUTICS | 24,530 | +0,20 % | Beam Therapeutics Inc. (NASDAQ:BEAM) Sees Large Increase in Short Interest | ||
ONCOLYTICS BIOTECH | 0,945 | 0,00 % | Oncolytics Biotech Inc. (NASDAQ:ONCY) Q3 2024 Earnings Call Transcript | ||
ARCTURUS THERAPEUTICS | 16,220 | +0,19 % | Arcturus Therapeutics Holdings Inc.: Arcturus Therapeutics to Present at Jefferies London Healthcare Conference | Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities... ► Artikel lesen | |
ASSERTIO | 0,950 | 0,00 % | Assertio Holdings-Direktorin Heather Mason kauft Aktien im Wert von 60.000 US-Dollar | ||
SIGA TECHNOLOGIES | 6,250 | 0,00 % | SIGA Technologies - TPOXX chalks up another DoD contract win | SIGA Technologies announced another contract win with the US Department of Defense (DoD), which is for the procurement of c $9m in TPOXX. This is the third DoD contract win in roughly three years for... ► Artikel lesen | |
ADMA BIOLOGICS | 21,470 | +0,47 % | Adma Biologics Aktie: Erholung nach starkem Kursrückgang |